NCT02213562已完成不适用
A Randomized, Double-blind, Parallel Group Study to Evaluate the Effect of Chrysanthemum Flower Oil and Its Dose-dependency in Subjects With Hyperuricemia
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 21
- 试验地点
- 1
- 主要终点
- Change in uric acid clearance from baseline
研究概览
简要总结
The aim of this study is to investigate the efficacy and dose-dependency of chrysanthemum flower oil in suppressing serum uric acid.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 30 Years 至 60 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Serum uric acid 6.8-8.9 mg/dL
排除标准
- •Taking anti-hyperuricemic drugs
- •History of gouty attack
- •Taking drugs or functional food that may affect serum uric acid level
- •Hypertention, hyperlipidemia, or diabetes millitus
- •Participation in any clinical trial within 90 days of the commencement of the trial
- •Renal or hepatic dysfunction
- •Heart disease
- •History of severe disease and/or major surgery
研究组 & 干预措施
200 mg CFO
Experimental
200 mg of chrysanthemum flower oil
干预措施: 200 mg of chrysanthemum flower oil (Dietary Supplement)
300 mg CFO
Experimental
300 mg of chrysanthemum flower oil
干预措施: 300 mg of chrysanthemum flower oil (Dietary Supplement)
400 mg CFO
Experimental
400 mg of chrysanthemum flower oil
干预措施: 400 mg of chrysanthemum flower oil (Dietary Supplement)
结局指标
主要结局
Change in uric acid clearance from baseline
时间窗: Every 4 weeks (Overall 8 weeks)
Change in serum uric acid from baseline
时间窗: Every 4 weeks (Overall 8 weeks)
次要结局
未报告次要终点
研究者
Fumiko Higashikawa
Associate Professor
Hiroshima University
研究点 (1)
Loading locations...
相似试验
Unknown
不适用
Study to Evaluate the Effect of a Vegetal Oil on Cognitive ImpairmentAlzheimer DiseaseCognitive ImpairmentsNCT02778581Team Foods Colombia S.A.110
已完成
3 期
Efficacy and Safety of Two Dosages of a Herbal Medicinal Product (Dry Extract BNO 1016) in Chronic RhinosinusitisChronic SinusitisNCT01706484Bionorica SE927
已完成
2 期
12 Week Evaluation of the Safety and Efficacy of 3 Doses of CP-526,555 and Placebo for Smoking CessationSmoking CessationNCT00139750Pfizer600
Unknown
不适用
CMI-168 on Cognitive Function in Healthy Middle-aged Men and WomenCognitive ChangeNCT03612752Cerebos Pacific Limited90
尚未招募
不适用
Efficacy and Safety Study of Essential Oil-Based Preparation Administered to COVID-19 PatientsCOVID-19 Respiratory InfectionCOVID-19NCT06452069Biodex S.A280